

Autumn 2021 WORKING GROUP MEETING MINUTES: Child Health

Meeting details		
Meeting location	Teleconference	
Meeting date	Wed 3 rd Nov 2021	
Meeting time	12:00-13:00 GMT	
Chair(s)	Steve Turner	
Attendees	James Paton Alan Kaplan	Theresa Guilbert Sarah Lucas
Objectives		
1	Update on current active projects	
2	Future projects	
3	New ideas	

Items	
	Paediatric Asthma in Real Life (PeARL) aims to identify and address key clinical questions and policy needs in pediatric asthma, resulting in the creation of evidence-based recommendations.
	 Systematic review evaluating maintenance management of pediatric asthma
Update on current	Challenging manuscript, because of the need to consider large amounts of data from all the systematic reviews included (>50). Hope to complete the first draft by mid-November.
projects	 Asthma monitoring questionnaire Data collection was completed early during September and currently they are being analysed including exploring differences among responder groups. Expect to finalize the manuscript by the end of the year
	3) Consensus Delphi Starting to plan soon, with a possibility of doing at least part of it live during the REG Summit 2022

Respiratory Effectiveness Group, ESpace North, 181 Wisbech Road, Littleport, Ely, Cambridgeshire, CB6 1RA, UK enquiries@effectivenessevaluation.org | effectivenessevaluation.org



	ICS Step Down in children and adults with asthma
Future projects	This study will consider ICS cessation, ICS dose reduction and step down to as required ICS/FABA in both children and adults with asthma. The outcomes will be exacerbations, the need to step up/reinitiate ICS and the factors that influence successful ICS cessation/step down. Protocol has been developed.
	Plan to fund this using money donated to the University of Aberdeen for respiratory research, but the University are yet to receive the money, so this project is currently on hold.
	Determining the prevalence of severe asthma in children in primary care.
	Protocol has been developed, although we still need to finalise the exact definitions of severe asthma and the criteria for biologic eligibility that will be used.
	Steve and Sarah had a call with Sanofi, who are interested in funding this. The proposal is going to UK Sanofi review on the 8th Nov and then will need to go to a global review. It is looking fairly positive at this stage.
	Sanofi were previously going to fund a similar project being run by Louise Fleming and Jenni Quint, but at the time Sanofi didn't have the funding. Louise and Jenni are continuing with their own CPRD project, but they will also be contributing their knowledge and experience to help with this project.
New ideas	Steve is working on the design of a clinical trial that will compare asthma outcomes between standard care versus standard care plus spirometry. He has sent 2 different scenarios and 2 questions on what are considered clinically important cut offs to a few colleagues to better understand how they use spirometry in decision making.
	There was some discussion around these questions, and it was suggested that a short survey monkey questionnaire could be put together to send to the REG Child Health WG and to others in REG that see children with asthma in either primary or secondary care to collect further responses. It might be possible to write a short communication on the results of this.
	ACTION POINT: Steve, Alan, Jimmy and Theresa will review the questions, and then REG will circulate the questionnaire to members.
	Next meeting: We are planning for face-to-face working group meetings at the REG summit in Barcelona, 17 th -19 th March 2022.

Respiratory Effectiveness Group, ESpace North, 181 Wisbech Road, Littleport, Ely, Cambridgeshire, CB6 1RA, UK enquiries@effectivenessevaluation.org | effectivenessevaluation.org